Paroxetine Tablet, Film Coated, Extended Release
Product Images NDC 62135-426

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Paroxetine (NDC 62135-426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Paroxetine Ext Rel Tab 12pt5mg 30s Bottle Label)

Label for Paroxetine Extended-Release Tablets, USP 12.5 mg from Chartwell RX, LLC. The orange and blue label indicates this is a prescription oral tablet package containing 30 extended-release film-coated tablets. It includes storage and handling instructions as well as a barcode and NDC 62135-425-30.*

FDA Label Image

Image Description (Paroxetine Ext Rel Tab 25mg 30s Bottle Label)

Label for Paroxetine Extended-Release Tablets, USP 25 mg by Chartwell RX, LLC. The label indicates the product contains 30 tablets for oral use, with dosage strength prominently displayed. It includes storage instructions, usage warnings, and directs users to an online medication guide. A barcode and manufacturing details are also visible.*

FDA Label Image

Image Description (Paroxetine Ext Rel Tab 37pt5mg 30s Bottle Label)

Paroxetine Extended-Release Tablets, USP 37.5 mg film-coated tablets in a carton containing 30 tablets. The label states 'Rx Only' and includes storage instructions between 20°C to 25°C. Manufactured by Chartwell RX, LLC, with labeling indicating Made in the USA. The packaging includes usage information, a barcode, and the NDC 62135-427-30.*

FDA Label Image

Image Description (Paroxetine Ext Rel Tab Figure 1)

A scatter plot chart showing fold changes and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of Paroxetine when co-administered with various interacting drugs including Pimozide, Desipramine, Propranolol, Digoxin, and Phenytoin. The x-axis is a log scale representing change relative to reference values, and data points illustrate increases or decreases in these parameters.*

FDA Label Image

Image Description (Paroxetine Ext Rel Tab Figure 2)

A forest plot chart showing the fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of Paroxetine when administered with interacting drugs: Cimetidine 300 mg three times daily, Phenobarbital 100 mg once daily, Phenytoin 300 mg once daily, Digoxin 0.25 mg once daily, and Diazepam 5 mg three times daily. The x-axis represents change relative to the reference, ranging from 0 to 2.*

FDA Label Image

Image Description (Paroxetine Ext Rel Tab Figure 3)

A pharmacokinetic chart depicting fold changes and 90% confidence intervals of paroxetine in various populations. The chart compares Cmax, AUC, and Cmin values across groups with renal impairment levels (mild, moderate, severe), hepatic impairment, different age groups (>65 years) with varying doses (20 mg, 30 mg, 40 mg once daily), and gender (males), relative to a reference value.*

FDA Label Image

Image Description (Paroxetine Ext Rel Tab Structure)

Chemical structure of Paroxetine hydrochloride showing the molecular arrangement including a fluorophenyl group and a tetrahydrofuran ring linked to a piperidine ring with a hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.